![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
MaxCyte, Inc. 14 June 2024 MaxCyte, Inc. ("MaxCyte" or the "Company") Grant of Options and Restricted Stock Units ROCKVILLE, MD, June 14, 2024: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT...
MaxCyte, Inc. 12 June 2024 MaxCyte, Inc. ("MaxCyte" or the "Company") Results of AGM Rockville, Maryland - June 12, 2024: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading...
kville, Maryland-based provider of cell engineering platform technologies - Says Chief Executive Officer Maher Masoud ...
MaxCyte, Inc. 11 June 2024 MaxCyte, Inc. ("MaxCyte" or the "Company") PDMR Dealing ROCKVILLE, MD, June 12, 2024: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering...
MaxCyte, Inc. 03 June 2024 MaxCyte, Inc. ("MaxCyte" or the "Company") Total Voting Rights and Block Listing Return ROCKVILLE, MD, June 3, 2024: MaxCyte, Inc., (Nasdaq: MXCT; LSE:...
MaxCyte, Inc. 29 May 2024 MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference Rockville, MD, May 29, 2024 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading...
ROCKVILLE, Md., May 29, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
kville, Maryland-based provider of cell engineering platform technologies developing "next-generation cell therapeutic ...
MaxCyte, Inc. 22 May 2024 4867-2449-5548v.1 MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development Legend...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -41 | -11.2328767123 | 365 | 365 | 323 | 19260 | 330.71470701 | DE |
4 | -51 | -13.6 | 375 | 405 | 323 | 16499 | 360.34786201 | DE |
12 | -11 | -3.28358208955 | 335 | 405 | 290 | 21260 | 349.85222842 | DE |
26 | -46 | -12.4324324324 | 370 | 420 | 290 | 31276 | 369.319807 | DE |
52 | -31 | -8.7323943662 | 355 | 420 | 172.5 | 30693 | 337.59435186 | DE |
156 | -576 | -64 | 900 | 1230 | 172.5 | 60958 | 638.67528225 | DE |
260 | 170 | 110.38961039 | 154 | 1230 | 105 | 87463 | 552.86645189 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions